In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Inventiva (NASDAQ:IVA – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...